Therefore, we hypothesize that S100A10 protects against liver tumor incidence specifically in a context of steatotic liver disease (LPTENKO and HFD-DEN) or in lipophagic, less aggressive tumors (mutated β-catenin tumors [16]) representing by itself around 30% of HCC patients. Here, S100A10 is linked to liver disorder.